Literature DB >> 6678879

Pharmacokinetics of high dose melphalan.

M R Hersh, T M Ludden, J G Kuhn, W A Knight.   

Abstract

A pharmacokinetic study of high dose intravenous melphalan, 180 mg/m2, was performed in eight patients. Plasma levels of melphalan declined in a biexponential fashion with a mean terminal half-life (t 1/2 beta) of 61 min (range 40.3-132.8 min). Estimated peak concentrations ranged from 5.45 to 16.57 mcg/ml. The average volume of distribution at steady state (Vdss) and clearance were 0.479 +/- 0.164 l/kg and 6.73 +/- 1.60 ml/min/kg, respectively. These kinetic parameters are similar to those reported from studies using lower doses of melphalan.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6678879     DOI: 10.1007/bf00177417

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  8 in total

1.  Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.

Authors:  M H Tattersall; M Jarman; E S Newlands; L Holyhead; R A Milstead; A Weinberg
Journal:  Eur J Cancer       Date:  1978-05       Impact factor: 9.162

2.  Pharmacology of intravenous melphalan in patients with multiple myeloma.

Authors:  L Brox; L Birkett; A Belch
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

3.  Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo.

Authors:  W R Bruce; B E Meeker; F A Valeriote
Journal:  J Natl Cancer Inst       Date:  1966-08       Impact factor: 13.506

4.  High-pressure liquid chromatographic analysis of melphalan in plasma.

Authors:  S Y Chang; D S Alberts; L R Melnick; P D Walson; S E Salmon
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

5.  Kinetics of intravenous melphalan.

Authors:  D S Alberts; S Y Chang; H S Chen; T E Moon; T L Evans; R L Furner; K Himmelstein; J F Gross
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

6.  Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Eur J Cancer Clin Oncol       Date:  1982-04

7.  Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy.

Authors:  D D Von Hoff; J Casper; E Bradley; J Sandbach; D Jones; R Makuch
Journal:  Am J Med       Date:  1981-05       Impact factor: 4.965

8.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

Authors:  T J McElwain; D W Hedley; G Burton; H M Clink; M Y Gordon; M Jarman; C A Juttner; J L Millar; R A Milsted; G Prentice; I E Smith; D Spence; M Woods
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

  8 in total
  8 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.

Authors:  Michael D Hadjidaniel; C Patrick Reynolds
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

3.  Development of a model of melphalan-induced gastrointestinal toxicity in mice.

Authors:  S Castellino; G B Elion; O W Griffith; M Dewhirst; J Kurtzberg; R C Cattley; P Scott; D D Bigner; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Fifty years of melphalan use in hematopoietic stem cell transplantation.

Authors:  Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-24       Impact factor: 5.742

6.  Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

Authors:  E Gomez; R Duléry; C Langlois; V Coiteux; L Terriou; L Magro; J Gauthier; E de Berranger; A Duhamel; I Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2014-09-15       Impact factor: 5.483

Review 7.  Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches.

Authors:  Anastazja Poczta; Aneta Rogalska; Agnieszka Marczak
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

8.  Effect of Primary and Secondary Beads of Carbon Enterosorbent on Haematological Parameters and Oxidative Stress Development Caused by Melphalan in Rats.

Authors:  Oksana Shevchuk; Elisaveta Snezhkova; Veronika Sarnatskaya; Victor Mikhailenko; Alexei Glavin; Lyudmyla Makovetska; Kvitoslava Bardakhivska; Inna Birchenko; Oleksandr Kozynchenko; Volodymyr Nikolaev
Journal:  Medicina (Kaunas)       Date:  2019-09-02       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.